三药联合方案治疗晚期结直肠癌的效果被引量：5

Efficacyof three-drugcombination plam in treatingadvanced colorectal cancer

导出

摘要目的比较5-氟尿嘧啶/亚叶酸联合伊立替康和奥沙利铂(FOLFIRINOX方案)和卡培他滨联合伊立替康和奥沙利铂(CAPIRINOX方案)在晚期结直肠癌的治疗效果。方法 64例晚期结直肠癌患者随机均分为FOLFIRINOX方案治疗组(A组)和CAPIRINOX方案治疗组(B组)。治疗6周后,评估两组临床疗效和不良反应。结果A组总有效率、中位无进展生存期和中位总生存期与B组比较无统计学差异(60.0%vs.61.3%、9.1个月vs.10.0个月和22.7个月vs.23.1个月)(P>0.05)。两组主要不良反应包括中性粒细胞下降、恶心、呕吐、脱发和周围神经毒性。结论FOLFIRINOX和CAPIRINOX方案均是治疗晚期结直肠癌的有效方案。 Objective To compare the efficacy of 5‐fluorouracil/leucovorin ,irinotecan and oxaliplatin（FOLFIRINOX plan） and capecitabine ,irinotecan and oxaliplatin（CAPIRINOX plan） in the treatment of advanced colorectal cancer .Methods A total of 64 patients with advanced colorectal cancer was equally randomized into two groups of A （treated with FOLFIRINOX plan ） and B（treated with CAPIRINOX plan） .The clinical outcomes and adverse effects were evaluated six weeks later . Results The overall response rate ,median progression‐free survival and median overall survival in group A were not statistically different from those in group B （60.0% vs .61.3% ,9.1 months vs .10.0 months and 22.7 months vs .23.1 months）（P〉0 .05） .The major adverse effects were decreased neutrophils ,nausea ,vomiting ,alopecia and peripheral neurotoxicity .Conclusion Both FOLFIRINOX plan and CAPIRINOX plan are effective in the treatment of advanced colorectal cancer .

作者李晟朱梁军潘良熹

机构地区江苏省肿瘤医院内科

出处《江苏医药》 CAS 2015年第12期1424-1426,共3页 Jiangsu Medical Journal

关键词结直肠癌伊立替康奥沙利铂 5-氟尿嘧啶卡培他滨 Colorectal cancer Irinotecan Oxaliplatin 5-Fluorouracil Capecitabine

分类号 R735 [医药卫生—肿瘤]

引文网络
相关文献

参考文献9

1吴在德,吴肇汉.外科学[M].第6版.北京:人民卫生出版社,2006:510.
2Malvezzi M,ArféA,Bertuccio P,et al.European cancer mortality predictions for the year 2011[J].Ann Oncol,2011,22(4):947-956.
3Goldberg RM.Therapy for metastatic colorectal cancer[J].Oncologist,2006,11(9):981-987.
4Falcone A,Ricci S,Brunetti I,et al.PhaseⅢtrial of infusional fluorouracil,leucovorin,oxaliplatin,and irinotecan(FOLFOXIRI)compared with infusional fluorouracil,leucovorin,and irinotecan(FOLFIRI)as first-line treatment for metastatic colorectal cancer:the Gruppo Oncologico Nord Ovest[J].J Clin Oncol,2007,25(13):1670-1676.
5Twelves C,Wong A,Nowacki MP,et al.Capecitabine as adjuvant treatment for stageⅢcolon cancer[J].N Engl J Med,2005,352(26):2696-2704.
6Cassidy J,Clarke S,Díaz-Rubio E,et al.Randomized phaseⅢstudy of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer[J].J Clin Oncol,2008,26(12):2006-2012.
7Cassidy J,Clarke S,Díaz-Rubio E,et al.XELOX vs FOLFOX-4as first-line therapy for metastatic colorectal cancer:NO16966updated results[J].Br J Cancer,2011,105(1):58-64.
8Zhang C,Wang J,Gu H,et al.Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer:Meta-analysis of randomized controlled trials[J].Oncol Lett,2012,3(4):831-838.
9Petrelli F,Cabiddu M,Barni S.5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer:apooled-analysis of randomized trials[J].Med Oncol,2012,29(2):1020-1029.